Payment overview · 2025
General Payments
$54.22
3 reported records · 3 companies
Healthcare provider profile · identity verified
Brian K Blackwell, MD
Allopathic & Osteopathic Physicians|General Practice · NEW CANTON, VA · NPI 1447238738
Verified facts
What the public records show
CMS Open Payments records show Brian K Blackwell, MD received $54.22 in general payments during 2025 across 3 reported records.
Gilead Sciences, Inc. accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.59 | 41.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.87 | 31.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.76 | 27.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $54.22 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| FLULAVAL QUADRIVALENT Normalized: flulaval quadrivalent |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 17 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
57 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 731 | 153 |
| Lisinopril | Lisinopril | 382 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 89 |
| Losartan Potassium | Losartan Potassium | 305 | 68 |
| Metformin Hcl Er | Metformin Hcl | 276 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 238 | 227 |
| Omeprazole | Omeprazole | 225 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 147 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 57 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 199 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 51 |
| Gabapentin | Gabapentin | 190 | 44 |
| Furosemide | Furosemide | 183 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 33 |
| Carvedilol | Carvedilol | 157 | 38 |
| Glimepiride | Glimepiride | 145 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 142 | 133 |
| Eliquis | Apixaban | 140 | 23 |
| Famotidine | Famotidine | 132 | 29 |
| Prednisone | Prednisone | 119 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 28 |
| Potassium Chloride | Potassium Chloride | 108 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 16 |
| Baclofen | Baclofen | 98 | 22 |
| Methylprednisolone | Methylprednisolone | 93 | 92 |
| Clonidine Hcl | Clonidine Hcl | 91 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 84 | 82 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 19 |
| Metformin Hcl | Metformin Hcl | 82 | 20 |
| Simvastatin | Simvastatin | 81 | 22 |
| Allopurinol | Allopurinol | 72 | 18 |
| Montelukast Sodium | Montelukast Sodium | 71 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 58 |
| Levetiracetam | Levetiracetam | 66 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 65 | 18 |
| Jardiance | Empagliflozin | 64 | 14 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 64 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 15 |
| Azithromycin | Azithromycin | 59 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | suppressed |
| Methocarbamol | Methocarbamol | 59 | 37 |
| Pregabalin | Pregabalin | 59 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 14 |
| Januvia | Sitagliptin Phosphate | 57 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 57 | 57 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Glipizide Er | Glipizide | 47 | suppressed |
| Spironolactone | Spironolactone | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 11 |
| Finasteride | Finasteride | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Atenolol | Atenolol | 39 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 14 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 23 |
| Meloxicam | Meloxicam | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 24 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Colchicine | Colchicine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 17 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Tri-Lo-Marzia | Norgestimate-Ethinyl Estradiol | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Cephalexin | Cephalexin | 12 | 12 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54.22 · 3 records | Gilead Sciences, Inc. | ABRYSVO, AREXVY, COMIRNATY, FLULAVAL QUADRIVALENT, PENBRAYA, PREVNAR 20, SHINGRIX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error